Condition
c-MET clinical trials and research
As of November 12, 2026, Find a Trial lists 5 c-MET clinical trials that are recruiting, at sites in 35 countries (most in China (5), Japan (5), United States (5)). By phase: Phase 2/3 (2), Phase 3 (1), Phase 2 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 35Countries
Newest c-MET clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| IV telisotuzumab adizutecan versus standard treatment for adults with advanced EGFR‑mutated non‑squamous NSCLC | Phase 2/3 | Springdale, Arkansas and 116 other locations | Recruiting | Sep 4, 2025 |
| Telisotuzumab adizutecan plus osimertinib for first-line treatment of advanced EGFR-mutated non-squamous NSCLC | Phase 2/3 | Chandler, Arizona and 64 other locations | Recruiting | Jun 5, 2025 |
| Evaluating a new treatment for advanced non-squamous lung cancer | Phase 1/2 | Phoenix, Arizona and 126 other locations | Recruiting | Jan 13, 2025 |
| Assessing the safety of telisotuzumab vedotin in adults with non-small cell lung cancer | Phase 2 | Chandler, Arizona and 82 other locations | Recruiting | Aug 23, 2024 |
| Comparing Telisotuzumab Vedotin and Docetaxel for Non-Small Cell Lung Cancer | Phase 3 | Birmingham, Alabama and 316 other locations | Recruiting | Jun 16, 2021 |
All recruiting trials (5)
-
IV telisotuzumab adizutecan versus standard treatment for adults with advanced EGFR‑mutated non‑squamous NSCLC
This trial tests whether IV telisotuzumab adizutecan works better than standard treatment for adults with advanced non‑squamous non‑small cell lung cancer that has EGFR exon 19 deletion or L858R mutation.
-
Telisotuzumab adizutecan plus osimertinib for first-line treatment of advanced EGFR-mutated non-squamous NSCLC
This test adds the investigational drug telisotuzumab adizutecan to osimertinib (or to osimertinib plus chemotherapy) to see if it helps adults with newly diagnosed advanced EGFR-mutated non-squamous non-small cell lung cancer and to check side effects.
-
Evaluating a new treatment for advanced non-squamous lung cancer
This study is testing a new combination of medications for adults with advanced lung cancer who haven't had treatment before, to see if it is safe and effective.
-
Assessing the safety of telisotuzumab vedotin in adults with non-small cell lung cancer
This study is testing a new drug called telisotuzumab vedotin to see if it is safe for adults with non-small cell lung cancer that has already been treated.
-
Comparing Telisotuzumab Vedotin and Docetaxel for Non-Small Cell Lung Cancer
This study is testing whether a new drug called telisotuzumab vedotin is better than the standard treatment docetaxel for adults with a specific type of lung cancer that has already been treated.
Related topics
Quick answers
How many c-MET clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 35 countries. The most sites are in China (5 trials), Japan (5 trials), United States (5 trials), Australia (4 trials), Belgium (4 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2/3: 2, Phase 3: 1, Phase 2: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.